Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial

Ángel Guerrero-Zotano, Miguel Gil-Gil, Amy Williams, Manuel Ruiz-Borrego, Hanna Ritzén, Eva María Ciruelos, Montserrat Muñoz, Begoña Bermejo, Mireia Margelí, Antonio Antón, Zsuzsanna Kahan, Tibor Csöszi, Laura Murillo, Serafín Morales Murillo, Istvan Lang, Cristina Reboredo Rendo, Emilio Alba, Pablo Álvarez, Juan de la Haba-Rodriguez, Isabel Álvarez, Andrés García, Jesús Herranz, Rosalía Caballero, Helle Fisker, Marta Portela, Federico Rojo, Miguel Martín

Open source

DOI
10.1016/j.ejca.2026.116817
Published
2026-06
Container
European Journal of Cancer
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2026.116817,
  title = {Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial},
  author = {Ángel Guerrero-Zotano and Miguel Gil-Gil and Amy Williams and Manuel Ruiz-Borrego and Hanna Ritzén and Eva María Ciruelos and Montserrat Muñoz and Begoña Bermejo and Mireia Margelí and Antonio Antón and Zsuzsanna Kahan and Tibor Csöszi and Laura Murillo and Serafín Morales Murillo and Istvan Lang and Cristina Reboredo Rendo and Emilio Alba and Pablo Álvarez and Juan de la Haba-Rodriguez and Isabel Álvarez and Andrés García and Jesús Herranz and Rosalía Caballero and Helle Fisker and Marta Portela and Federico Rojo and Miguel Martín},
  year = {2026},
  journal = {European Journal of Cancer},
  doi = {10.1016/j.ejca.2026.116817},
  url = {https://doi.org/10.1016/j.ejca.2026.116817}
}

RIS

TY  - JOUR
TI  - Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial
AU  - Ángel Guerrero-Zotano
AU  - Miguel Gil-Gil
AU  - Amy Williams
AU  - Manuel Ruiz-Borrego
AU  - Hanna Ritzén
AU  - Eva María Ciruelos
AU  - Montserrat Muñoz
AU  - Begoña Bermejo
AU  - Mireia Margelí
AU  - Antonio Antón
AU  - Zsuzsanna Kahan
AU  - Tibor Csöszi
AU  - Laura Murillo
AU  - Serafín Morales Murillo
AU  - Istvan Lang
AU  - Cristina Reboredo Rendo
AU  - Emilio Alba
AU  - Pablo Álvarez
AU  - Juan de la Haba-Rodriguez
AU  - Isabel Álvarez
AU  - Andrés García
AU  - Jesús Herranz
AU  - Rosalía Caballero
AU  - Helle Fisker
AU  - Marta Portela
AU  - Federico Rojo
AU  - Miguel Martín
PY  - 2026
JO  - European Journal of Cancer
DO  - 10.1016/j.ejca.2026.116817
UR  - https://doi.org/10.1016/j.ejca.2026.116817
ER  -

APA

Guerrero-Zotano, Á., Gil-Gil, M., Williams, A., Ruiz-Borrego, M., Ritzén, H., Ciruelos, E. M., Muñoz, M., Bermejo, B., Margelí, M., Antón, A., Kahan, Z., Csöszi, T., Murillo, L., Murillo, S. M., Lang, I., Rendo, C. R., Alba, E., Álvarez, P., Haba-Rodriguez, J. D. L., Álvarez, I., García, A., Herranz, J., Caballero, R., Fisker, H., Portela, M., Rojo, F., & Martín, M. (2026). Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116817

Source records